<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04424290</url>
  </required_header>
  <id_info>
    <org_study_id>1436-0001</org_study_id>
    <secondary_id>2019-004432-28</secondary_id>
    <nct_id>NCT04424290</nct_id>
  </id_info>
  <brief_title>HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia</brief_title>
  <acronym>HORNBILL</acronym>
  <official_title>A First-in Human Trial to Study Safety and Tolerability of Single Rising Intravitreal dOses (Open Label, Non-randomized, Uncontrolled) and in Addition the Early Biological Response of Multiple intravitReal Dosing (Single-masked, raNdomized, Sham-controlled) of BI 764524 in panretinaL Photocoagulation (PRP) Treated proLiferative Diabetic Retinopathy (PDR) Patients With Diabetic Macular Ischemia (DMI) - the HORNBILL Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study in people with a type of diabetic eye disease called diabetic retinopathy&#xD;
      with diabetic macular ischemia. People who have had laser treatment for their diabetic&#xD;
      retinopathy can participate in the study. The laser treatment is called panretinal&#xD;
      photocoagulation.&#xD;
&#xD;
      The purpose of the study is to find out how well different doses of a medicine called BI&#xD;
      764524 are tolerated. BI 764524 is injected into the eye. The study has 2 parts. In the first&#xD;
      part, participants get different doses of BI 764524 only once. Participants are in the first&#xD;
      part for about 5 months and visit the study site about 8 times. In the second part,&#xD;
      participants are put into different groups by chance. Some participants get BI 764524&#xD;
      injections every 4 weeks. Other participants get sham injections every 4 weeks. A sham&#xD;
      injection means that it is not a real injection and contains no medicine. Participants cannot&#xD;
      tell whether they get the real injection or a sham injection. For the second part,&#xD;
      participants are in the study for about 7 months. During this time, they visit the study site&#xD;
      about 7 times. In this study, BI 764524 is given to humans for the first time.&#xD;
&#xD;
      The doctors compare how well people tolerate the BI 764524 injections and the sham&#xD;
      injections.&#xD;
&#xD;
      The doctors also regularly check the general health of the participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2020</start_date>
  <completion_date type="Anticipated">October 19, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 19, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>This trial will consist of an single rising dose (SRD) part followed by an multiple dosing (MD) part. SRD part will be nonrandomized, open-label, and uncontrolled. MD part will be single-masked, randomized and sham-controlled (Ratio 2:1). Parties masked in the MD part are participant and masked site staff (including investigator). The Intervention model in the MD part is active group versus sham injection (=2 arms).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Single rising dose (SRD) part: Number of participants with dose limiting events</measure>
    <time_frame>14 weeks</time_frame>
    <description>Number of patients with dose limiting events (DLEs) from drug administration till day 8 (7 days after treatment).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple dosing (MD) part: Number of patients with drug related adverse events (AEs) from drug administration till end of study (EOS)</measure>
    <time_frame>22 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>SRD part: Number of patients with drug related AEs at EOS</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SRD part: Number of patients with ocular AEs (eye disorders) at EOS</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MD part: Change from baseline of the size of the foveal avascular zone (FAZ) in optical coherence tomography angiography (OCTA) in superficial and combined vascular complex at Visit 5</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MD part: Change from baseline of the size of the FAZ in OCTA in superficial and combined vascular complex at Visit 7</measure>
    <time_frame>22 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MD part: Change from baseline of best corrected visual acuity (BCVA) at Visit 3</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MD part: Change from baseline of BCVA at Visit 4</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MD part: Change from baseline of BCVA at Visit 5</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MD part: Change from baseline of BCVA at Visit 6</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MD part: Change from baseline of BCVA at Visit 7</measure>
    <time_frame>22 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MD part: Change from baseline of central retinal thickness (SD-OCT) at Visit 3</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MD part: Change from baseline of central retinal thickness (SD-OCT) at Visit 4</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MD part: Change from baseline of central retinal thickness (SD-OCT) at Visit 5</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MD part: Change from baseline of central retinal thickness (SD-OCT) at Visit 6</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MD part: Change from baseline of central retinal thickness (SD-OCT) at Visit 7</measure>
    <time_frame>22 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MD part: Number of patients with ocular AEs at EOS</measure>
    <time_frame>22 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>BI 764524</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single rising dose part followed by a multiple dosing part.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 764524</intervention_name>
    <description>Powder for solution for intravitreal injection.</description>
    <arm_group_label>BI 764524</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Single rising dose (SRD) and multiple dosing (MD) part:&#xD;
&#xD;
          -  Pan-retinal photo coagulation treated proliferative diabetic retinopathy (PDR)&#xD;
             participants with either no or inactive retinal neovascularization per investigator&#xD;
             judgement in the study eye&#xD;
&#xD;
          -  Male or female participants of age ≥ 18 years&#xD;
&#xD;
          -  HbA1c of ≤ 12.0%&#xD;
&#xD;
          -  Best-corrected Visual activity (VA) in the non-study eye better than best-corrected VA&#xD;
             in the study-eye, if both eyes are eligible and have identical VA the investigator may&#xD;
             select the study eye.&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) and men able to father a child must be ready&#xD;
             and able to use two methods of contraception with at least one of them being a highly&#xD;
             effective methods of birth control per ICH M3 (R2) that result in a low failure rate&#xD;
             of less than 1% per year when used consistently and correctly. A list of contraception&#xD;
             methods meeting these criteria is provided in the patient information and in the&#xD;
             clinical trial protocol.&#xD;
&#xD;
             --A woman is considered of childbearing potential (WOCBP), i.e. fertile, following&#xD;
             menarche and until becoming postmenopausal unless permanently sterile. Permanent&#xD;
             sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral&#xD;
             oophorectomy. Tubal ligation is NOT a method of permanent sterilisation. A&#xD;
             postmenopausal state is defined as no menses for 2 years without an alternative&#xD;
             medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal&#xD;
             range may be used to confirm a post-menopausal state in women not using hormonal&#xD;
             contraception or hormonal replacement therapy. However in the absence of 2 years of&#xD;
             menorrhea, a single FSH measurement is sufficient.&#xD;
&#xD;
          -  Signed and dated written informed consent in accordance with ICH Harmonized Guideline&#xD;
             for Good Clinical Practice (ICH GCP) and local legislation prior to admission to the&#xD;
             trial&#xD;
&#xD;
        SRD part only:&#xD;
&#xD;
          -  Evidence of diabetic macular ischemia (DMI) per investigator´s judgement, defined as&#xD;
             any degree of disruption of retinal vascularity in superficial and/or deep retinal&#xD;
             plexus in OCTA&#xD;
&#xD;
          -  Best-corrected VA ≤55 letters (20/80) or worse&#xD;
&#xD;
        MD part only:&#xD;
&#xD;
          -  Presence of significant DMI: large foveal avascular zone defined as those with ≥0.5mm2&#xD;
             area in superficial vascular complex (SVC) present on optical coherence tomography&#xD;
             angiography. If FAZ is &lt;0.5mm2 then enlarged peri-foveal inter-capillary space in at&#xD;
             least 1 quadrant will be sufficient.&#xD;
&#xD;
          -  Best-corrected VA ≤ 85 letters (20/20) or worse&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        SRD part only:&#xD;
&#xD;
          -  Participants receiving intravitreal (IVT) injections for active diabetic macular edema&#xD;
             (DME, injections: anti-vascular endothelial growth factor (VEGF), steroids) and&#xD;
             macular laser in the study eye in the previous 3 months prior to enrolment&#xD;
&#xD;
          -  Participants receiving anti-VEGF IVT injections for active PDR in the study eye in the&#xD;
             previous 3 months prior to enrolment&#xD;
&#xD;
          -  Current or planned use of medications known to be toxic to the retina, lens or optic&#xD;
             nerve (e.g. desferoximine, chloroquine/hydrochloroquine, chlorpromazine,&#xD;
             phenothiazines, tamoxifen, nicotinic acid, and ethambutol)&#xD;
&#xD;
          -  Additional eye disease in the study eye that could compromise best corrected VA (BCVA)&#xD;
             with visual field loss, uncontrolled glaucoma (IOP&gt;24), age related macular&#xD;
             degeneration, history of ischemic optic neuropathy or retinal vascular occlusion,&#xD;
             symptomatic vitreomacular traction, or genetic disorders such as retinitis pigmentosa;&#xD;
             history of high myopia &gt; 8 diopters in the study eye. Anterior segment and vitreous&#xD;
             abnormalities in the study eye that would preclude adequate observation with SD-OCT&#xD;
&#xD;
          -  Any intraocular surgery in the study eye within 3 months prior to screening&#xD;
&#xD;
          -  Aphakia or total absence of the posterior capsule. Yttrium aluminium garnet (YAG)&#xD;
             laser capsulotomy in the study eye if performed less than 3 months prior to enrolment&#xD;
&#xD;
          -  Participants not expected to comply with the protocol requirements or not expected to&#xD;
             complete the trial as scheduled (e.g. chronic alcohol or drug abuse or any other&#xD;
             condition that, in the investigator´s opinion, makes the patient an unreliable trial&#xD;
             participant)&#xD;
&#xD;
          -  Previous participation in this trial or in other trials with IVT injections&#xD;
             administered within 3 months.&#xD;
&#xD;
        Further exclusion criteria apply.&#xD;
&#xD;
        MD part only:&#xD;
&#xD;
          -  DME, defined as a central subfield thickness (CST) ≥305 micrometer (μm) for men and&#xD;
             ≥290 μm women measured with optovue (Optical coherent tomography) OCT in the study eye&#xD;
&#xD;
          -  Participants receiving IVT injections for active DME (anti-VEGF, steroids) and macular&#xD;
             laser in the study eye in the previous 3 months prior to enrolment&#xD;
&#xD;
          -  Participants receiving anti-VEGF IVT injections for active PDR in the study eye in the&#xD;
             previous 3 months prior to enrolment&#xD;
&#xD;
          -  Heavily lasered macula in the study eye per investigator's judgement&#xD;
&#xD;
          -  History of vitrectomy in the study eye&#xD;
&#xD;
          -  Epiretinal membrane with extended foveal contour distortion in the study eye per&#xD;
             investigator's judgement&#xD;
&#xD;
          -  Clinically significant disorganisation of retinal inner layer (DRIL) in the study eye&#xD;
&#xD;
          -  Current or planned use of medications known to be toxic to the retina, lens or optic&#xD;
             nerve (e.g. desferoximine, chloroquine/hydrochloroquine, chlorpromazine,&#xD;
             phenothiazines, tamoxifen, nicotinic acid, and ethambutol) Further exclusion criteria&#xD;
             apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Trinity Research</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harsha Sen</last_name>
      <phone>+001(334)793-2211</phone>
      <email>hsen@eyecentersouth.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retina-Vitreous Associates Medical Group</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Boyer</last_name>
      <phone>+001(213)483-8810</phone>
      <email>vitdoc@aol.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quan Nguyen</last_name>
      <phone>+001(650)724-4280</phone>
      <email>ndquan@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Retina Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Cunningham</last_name>
      <phone>+001(407)849-9621</phone>
      <email>macunning@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Raj K. Maturi, MD PC</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raj Maturi</last_name>
      <phone>+001(317)817-1414</phone>
      <email>rmaturi@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Joslin Diabetes Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Sun</last_name>
      <phone>+001(617)309-2554</phone>
      <email>jennifer.sun@joslin.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Long Island Vitreoretinal Consultants</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Rhee</last_name>
      <phone>+001(516)466-0390</phone>
      <email>drhee@longislandretina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York Eye and Ear Infirmary of Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Rosen</last_name>
      <phone>+001(212)979-4288</phone>
      <email>rrosen@nyee.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Talcott</last_name>
      <phone>+001(216)636-0183</phone>
      <email>talcotk@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retina Research Institute of Texas</name>
      <address>
        <city>Abilene</city>
        <state>Texas</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sunil Patel</last_name>
      <phone>+001(325)690-4414</phone>
      <email>dr.patel@txicr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Austin Research Center for Retina, PLLC</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chirag Jhaveri</last_name>
      <phone>+001(512)279-1251</phone>
      <email>cjhaveri@e-retina.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Texas</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Brown</last_name>
      <phone>+001(713)524-3434</phone>
      <email>dmbmd@retinaconsultantstexas.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Valley Retina Institute, PA</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Gonzalez</last_name>
      <phone>+001(956)631-8875-x118</phone>
      <email>Research@vritx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Texas</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Wykoff</last_name>
      <phone>+001(936)273-6620</phone>
      <email>ccwmd@houstonretina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bristol Eye Hospital</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abosede Cole</last_name>
      <phone>01173424770</phone>
      <email>a.cole@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gloucestershire Royal Hospital</name>
      <address>
        <city>Gloucester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quresh Mohamed</last_name>
      <phone>03004223149</phone>
      <email>quresh.mohamed@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sobha Sivaprasad</last_name>
      <phone>02075662117</phone>
      <email>Sobha.sivaprasad@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunderland Eye Infirmary</name>
      <address>
        <city>Sunderland</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maged Habib</last_name>
      <phone>01915699039</phone>
      <email>Maged.Habib@chsft.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southend General Hospital</name>
      <address>
        <city>Westcliff-on-Sea</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niral Karia</last_name>
      <phone>+441702435555</phone>
      <email>Niral.Karia@southend.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 8, 2020</study_first_submitted>
  <study_first_submitted_qc>June 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2020</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions: 1. studies in products where Boehringer Ingelheim is not the license holder; 2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; 3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).For more details refer to: https://www.mystudywindow.com/msw/datasharing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

